Search details
1.
ctDNA improves prognostic prediction in relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone.
Blood
; 2024 Mar 01.
Article
in English
| MEDLINE | ID: mdl-38427753
2.
A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan.
Ann Hematol
; 103(2): 475-488, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37695378
3.
Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs.
Haematologica
; 108(12): 3399-3408, 2023 12 01.
Article
in English
| MEDLINE | ID: mdl-37470160
4.
Myeloid Sarcoma of the Paranasal Sinuses in a Patient with Acute Myeloid Leukemia.
Tohoku J Exp Med
; 246(2): 141-146, 2018 10.
Article
in English
| MEDLINE | ID: mdl-30369515
5.
Outcomes of adult patients with early T-cell precursor (ETP) acute lymphoblastic leukemia/lymphoma (ALL) and non-ETP T-ALL.
Int J Hematol
; 117(5): 738-747, 2023 May.
Article
in English
| MEDLINE | ID: mdl-36757523
6.
Outcomes of poor peripheral blood stem cell mobilizers with multiple myeloma at the first mobilization: A multicenter retrospective study in Japan.
EJHaem
; 3(3): 838-848, 2022 Aug.
Article
in English
| MEDLINE | ID: mdl-36051061
7.
Rapid progression of left ventricular hypertrophy caused by leukaemic infiltration of myocardium.
Eur Heart J Cardiovasc Imaging
; 24(4): e60, 2023 03 21.
Article
in English
| MEDLINE | ID: mdl-36637875
Results
1 -
7
de 7
1
Next >
>>